Merck & Company, Inc. (NYSE:MRK) has been given a $70.00 target price by stock analysts at BMO Capital Markets in a research report issued to clients and investors on Wednesday. The firm presently has a “buy” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 9.75% from the company’s previous close.

MRK has been the subject of several other research reports. Cowen and Company reaffirmed a “hold” rating and set a $70.00 target price on shares of Merck & in a research report on Friday, September 1st. Zacks Investment Research cut Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Credit Suisse Group reaffirmed a “buy” rating on shares of Merck & in a research report on Tuesday, June 13th. Jefferies Group LLC reaffirmed a “sell” rating and set a $52.00 target price on shares of Merck & in a research report on Sunday, August 20th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $74.00 target price (up previously from $70.00) on shares of Merck & in a research report on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $69.69.

Shares of Merck & (NYSE MRK) traded down 1.05% during trading on Wednesday, hitting $63.78. 10,101,320 shares of the stock were exchanged. The stock has a market cap of $173.95 billion, a P/E ratio of 34.53 and a beta of 0.80. Merck & has a 12-month low of $58.29 and a 12-month high of $66.80. The stock has a 50-day moving average of $64.42 and a 200 day moving average of $63.70.

Merck & (NYSE:MRK) last released its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter in the previous year, the business posted $0.93 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. Equities analysts predict that Merck & will post $3.87 earnings per share for the current fiscal year.

WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/11/merck-company-inc-mrk-given-a-70-00-price-target-at-bmo-capital-markets.html.

Several hedge funds have recently made changes to their positions in MRK. Perennial Advisors LLC boosted its holdings in Merck & by 10.7% in the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after acquiring an additional 157 shares during the last quarter. Stelac Advisory Services LLC bought a new position in Merck & in the second quarter valued at about $104,000. Vigilant Capital Management LLC boosted its holdings in Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after acquiring an additional 250 shares during the last quarter. Cascade Investment Advisors Inc. boosted its holdings in Merck & by 15.5% in the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the last quarter. Finally, Solaris Asset Management LLC boosted its holdings in Merck & by 6.3% in the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.